Judith M Bliss - JoVE Visualize

Showing results (11-20 of 98) with videos related to

Pageof 10

Sort By:

International Journal of Radiation Oncology, Biology, Physics|May 18, 2010

Ipsilateral breast tumor relapse: local recurrence versus new primary tumor and the effect of whole-breast radiotherapy on the rate of new primariesDorothy M Gujral, Georges Sumo, John R Owen, et al.

The Lancet. Oncology|January 24, 2012

Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane StudyJ Sven D Mieog, James P Morden, Judith M Bliss, et al.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 22, 2019

Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trialIndrani S Bhattacharya, Joanne S Haviland, Penelope Hopwood, et al.

The Lancet. Oncology|January 22, 2016

Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trialAndrew J Hayes, Lauren Maynard, Gillian Coombes, et al.

The Lancet. Oncology|June 6, 2006

Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trialJ Roger Owen, Anita Ashton, Judith M Bliss, et al.

Trials|May 7, 2022

Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancerClaire Snowdon, Sarah Kernaghan, Laura Moretti, et al.

NPJ Breast Cancer|February 13, 2021

Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapiesJohn F R Robertson, Angelo Di Leo, Stephen Johnston, et al.

European Thyroid Journal|September 5, 2017

TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001)Ilaria Muller, Lucy S Kilburn, Peter N Taylor, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2006

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancerLesley J Fallowfield, Judith M Bliss, Lucy S Porter, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2018

Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled TrialIndrani S Bhattacharya, Joanne S Haviland, Anna M Kirby, et al.

Pageof 10

Showing results (11-20 of 98) with videos related to

Sort By:

Pageof 10

International Journal of Radiation Oncology, Biology, Physics|May 18, 2010

Ipsilateral breast tumor relapse: local recurrence versus new primary tumor and the effect of whole-breast radiotherapy on the rate of new primariesDorothy M Gujral, Georges Sumo, John R Owen, et al.

The Lancet. Oncology|January 24, 2012

Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane StudyJ Sven D Mieog, James P Morden, Judith M Bliss, et al.

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 22, 2019

Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trialIndrani S Bhattacharya, Joanne S Haviland, Penelope Hopwood, et al.

The Lancet. Oncology|January 22, 2016

Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trialAndrew J Hayes, Lauren Maynard, Gillian Coombes, et al.

The Lancet. Oncology|June 6, 2006

Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trialJ Roger Owen, Anita Ashton, Judith M Bliss, et al.

Trials|May 7, 2022

Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancerClaire Snowdon, Sarah Kernaghan, Laura Moretti, et al.

NPJ Breast Cancer|February 13, 2021

Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapiesJohn F R Robertson, Angelo Di Leo, Stephen Johnston, et al.

European Thyroid Journal|September 5, 2017

TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001)Ilaria Muller, Lucy S Kilburn, Peter N Taylor, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2006

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancerLesley J Fallowfield, Judith M Bliss, Lucy S Porter, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2018

Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled TrialIndrani S Bhattacharya, Joanne S Haviland, Anna M Kirby, et al.

Pageof 10